Imatinib as a paradigm of targeted therapies

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 239s-245s

  Druker, Brian J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ARTICLE; AWARDS AND PRIZES; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; HUMAN; ONCOLOGY;

ANTINEOPLASTIC AGENTS; AWARDS AND PRIZES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MEDICAL ONCOLOGY; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0642307264     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.589     Document Type: Article

References (49)

1. Bennett JH: Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb Med Surg J 64: 413-423, 1845
2. Virchow R: Weisses Blut. Froriep's Notizen 36: 151-156, 1845
3. Geary CG: The story of chronic myeloid leukaemia. Br J Haematol 110: 2-11, 2000
4. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497, 1960
5. Rowley JD: A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243: 290-293, 1973
6. de Klein A, van Kessel AG, Grosveld G, et al: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300: 765-767, 1982
7. Shtivelman E, Lifshitz B, Gale RP, et al: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550-554, 1985
8. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, et al: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233: 212-214, 1986
9. Davis RL, Konopka JB, Witte ON: Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5: 204-213, 1985
10. Heisterkamp N, Jenster G, ten Hoeve J, et al: Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251-253, 1990
11. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990
12. Rous P: A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 13: 397-411, 1911
13. Stehelin D, Varmus HE, Bishop JM, et al: DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170-173, 1976
14. Eckhart W, Hutchinson MA, Hunter T: An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 18: 925-933, 1979
15. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med 2: 561-566, 1996
16. Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000
17. Druker BJ, Talpaz M, Resta D, et al: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001
18. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652, 2002
19. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99: 1928-1937, 2002
20. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood 99: 3530-3539, 2002
21. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003
22. Oda T, Heaney C, Hagopian J, et al: CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269: 22925-22928, 1994
23. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001
24. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472-3475, 2002
25. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196, 2002
26. Hofmann WK, Jones LC, Lemp NA, et al: Ph(-) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99: 1860-1862, 2002
27. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018, 2002
28. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125, 2002
29. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosomepositive leukaemia to STI571: A prospective study. Lancet 359: 487-491, 2002
30. Corbin AS, Buchdunger E, Pascal F, et al: Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 277: 32214-32219, 2002
31. Corbin AS, La Rosée P, Stoffregen E, et al: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611-4614, 2003
32. La Rosee P, Corbin AS, Stoffregen EP, et al: Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62: 7149-7153, 2002
33. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465, 2002
34. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998
35. Rubin BP, Singer S, Tsao C, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121, 2001
36. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002
37. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358: 1421-1423, 2001
38. Heinrich MC, Corless CL, Blanke CD, et al: KIT mutational status predicts response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21: 2a, 2002
39. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710, 2003
40. Ottmann OG, Druker BJ, Sawyers CL, et al: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosomepositive acute lymphoid leukemias. Blood 100: 1965-1971, 2002
41. Golub TR, Barker GF, Lovett M, et al: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell 77: 307-316, 1994
42. Maki RG, Awan RA, Dixon RH, et al: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100: 623-626, 2002
43. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20: 3586-3591, 2002
44. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481-487, 2002
45. Magnusson MK, Meade KE, Nakamura R, et al: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100: 1088-1091, 2002
46. Simon MP, Pedeutour F, Sirvent N, et al: Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 15: 95-98, 1997
47. Gleich GJ, Leiferman KM, Pardanani A, et al: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359: 1577-1578, 2002
48. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214, 2003
49. Griffin JH, Leung J, Bruner RJ, et al: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 100: 7830-7835, 2003